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Abstract: Type 1 diabetes (T1D) is characterized by the immune-mediated destruction of
insulin-producing islet β cells. Biomarkers capable of identifying T1D risk and dissecting
disease-related heterogeneity represent an unmet clinical need. Toward the goal of informing
T1D biomarker strategies, we profiled coding and noncoding RNAs in human islet-derived exosomes
and identified RNAs that were differentially expressed under proinflammatory cytokine stress
conditions. Human pancreatic islets were obtained from cadaveric donors and treated with/without
IL-1β and IFN-γ. Total RNA and small RNA sequencing were performed from islet-derived exosomes
to identify mRNAs, long noncoding RNAs, and small noncoding RNAs. RNAs with a fold change≥1.3
and a p-value <0.05 were considered as differentially expressed. mRNAs and miRNAs represented
the most abundant long and small RNA species, respectively. Each of the RNA species showed altered
expression patterns with cytokine treatment, and differentially expressed RNAs were predicted
to be involved in insulin secretion, calcium signaling, necrosis, and apoptosis. Taken together,
our data identify RNAs that are dysregulated under cytokine stress in human islet-derived exosomes,
providing a comprehensive catalog of protein coding and noncoding RNAs that may serve as potential
circulating biomarkers in T1D.
Keywords: islet-derived exosomes; mRNA; long noncoding RNA; small noncoding RNA; total RNA
sequencing; small RNA sequencing
1. Introduction
Type 1 diabetes (T1D) is characterized by the immune-mediated destruction of the pancreatic β
cells, resulting in the lifelong need for exogenous insulin treatment. Over the past 30 years, considerable
effort has been directed toward identifying therapies capable of inducing T1D remission and immune
tolerance. A handful of interventions have shown modest efficacy in preserving C-peptide secretion
when initiated at stage 3 T1D onset [1–4]. Recently, an anti-CD3 monoclonal antibody (teplizumab)
delayed the onset of T1D by approximately two years in high-risk individuals [5], providing support
to the notion that T1D is a preventable disease. However, despite these recent successes, T1D clinical
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trial efforts continue to be challenged by marked heterogeneity in treatment responses among study
populations. Similarly, there is significant heterogeneity in disease progression in autoantibody positive
at-risk individuals, thus highlighting the need for improved methods to identify those who should be
targeted with immunomodulatory interventions.
Biomarkers that reliably detect β cell stress and death may aid in dissecting T1D-related
heterogeneity. In recent years, healthy as well as diseased cells have been shown to release
a heterogenous population of membrane bound vesicles known as extracellular vesicles (EVs) [6].
EVs can be classified into several subtypes, including microvesicles, exosomes, and apoptotic bodies,
based on their size, origin, biogenesis, and release pathways [7]. Exosomes, which are defined
as an EV population with a diameter of ~100 nm, have been implicated in a variety of molecular
pathways relevant to T1D, including immune regulation, antigen presentation, programmed cell death,
and inflammation [7]. In addition, exosomes are known to transport cellular contents such as nucleic
acids and proteins, which can be transferred to recipient cells where they can facilitate intercellular
communication as well as disease pathogenesis. As the exosome cargo may also change during disease
evolution, cell-specific exosome signatures may serve as circulating biomarkers [8].
In the context of type 1 diabetes, islet-derived EVs released during inflammatory β cell stress
have been shown to contain β-cell-specific autoantigens, such as GAD65, IA-2, and proinsulin [9].
Exosomes may also act as a communication bridge between immune cells and insulin secreting cells.
Recently, Guay et al. demonstrated that specific contents of exosomes released from lymphocytes can
induce β cell apoptosis [10]. Likewise, pancreatic islets have also been shown to secrete EVs that act in
an autocrine manner to regulate β cell proliferation and death [11].
Toward the goal of informing the development of exosome biomarkers in T1D, the objective of
this study was to profile the various classes of protein coding and noncoding exosome-associated
RNAs in human cadaveric islet-derived exosomes treated with IL-1β and IFN-γ, an ex vivo exposure
model intended to mimic the proinflammatory milieu of T1D. Since EVs are found to be enriched in
nucleic acid species, our primary aim was to profile mRNAs and noncoding RNAs, including long
noncoding RNAs (lncRNAs), micro RNAs (miRNAs), piwi-interacting RNAs (piRNAs), transfer RNAs
(tRNAs), and small nucleolar RNAs (snoRNAs). Our results show that islet-derived exosomes express
multiple classes of RNAs, with mRNAs (and their associated fragments) being the most abundant class
of long RNAs and miRNAs being the most abundant class among the known small noncoding RNAs.
In addition to generating a RNA landscape of islet-derived exosomes in T1D, our results revealed
alteration in the expression pattern of every class of RNA profiled, suggesting that newer classes of
RNAs have the potential to emerge as circulating biomarkers for T1D.
2. Results
2.1. Characterization of Exosomes
The overall workflow for this study is shown in Figure 1. Exosomes were isolated from
human islet cell culture supernatants using ExoQuick (SBI Biosciences, Palo Alto, CA, USA). The
nanoparticle tracking analysis (NTA) of isolated exosomes showed a mean particle size of 131.56 ±
3.72 nm and 125.3 ± 6.01 nm from supernatants of human islets treated with or without cytokines,
respectively (Figure 2a,b). Immunoblot analysis of isolated exosomes confirmed the presence of known
exosomal markers tetraspanin CD9 and CD63 (Figure 2c). Electron microscopy analysis (TEM) was
performed to visualize the exosomes and confirmed the presence of round double membrane vesicles
measuring <150 nm in size in both cytokine and control-treated islets (Figure 2d).
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Figure 1. Workflow of the study: human islet-derived exosomes were treated with/without IL-1β and 
IFN-γ for 24 h and then subjected to total RNA sequencing and small RNA sequencing to profile 
protein coding and noncoding RNAs (long and small). The functions of differentially expressed 
RNAs were identified using the Ingenuity Pathway analysis tool. 
 
Figure 2. Characterization of exosomes: nanoparticle tracking analysis was performed to profile 
extracellular vesicle (EV) particle concentration (A) and size distribution (B) in control and human 
cytokine-treated islet-derived exosomes (n = 3), (C) immunoblot was performed using antibodies 
against CD63 and CD9, and (D) TEM imaging was performed to confirm the presence of exosomes. 
Figure 1. Workflow of the study: islet-derived exosomes were treated with/without IL-1β
and IFN-γ for 24 h and then subjected to total RNA sequencing and small RNA sequencing to profile
protein coding and noncoding RNAs (long and small). The functions of differentially expressed RNAs
were identified using the Ingenuity Pathway analysis tool.
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Figure 2. Characterization of exosomes: nano article tracking analysis was performed to profile
extracellular vesicle (EV) particle concentration (A) and size distribution (B) in control and human
cytokine-treated islet-derived exosomes (n = 3), (C) immunoblot was performed using antibodies
against CD63 and CD9, and (D) TEM imaging was performed to confirm the presence of exosomes.
Shown is a representative image of exosomes from untreated islets. Representative exosomes are
indicated with a red arrow. Scale bar: 100 nm.
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2.2. Descriptive Statistics of Total RNA and Small RNA Sequencing Profiles
From the total RNAseq protocol, approximately 37 million and 34 million reads were detected
from control and cytokine-treated samples, respectively. In both control and cytokine-treated human
islet-derived exosomes, 69% of the reads mapped to protein coding mRNAs and ~21% of the reads
mapped to long noncoding RNAs (Figure 3a). For both mRNAs and lncRNAs, the length distribution
of the majority of the reads ranged from 72 to 76 nt in both control and cytokine-treated samples
(Figure 3b). These 72–76 nt long RNAs represented fragments of full-length mRNAs and lncRNAs.
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2.3. Long and Small RNAs Are Differentially Expressed in Cytokine-Treated Islet-Derived Exosomes 
Since the primary aim of our study was to identify potential circulating RNA biomarkers for 
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retained only those RNAs that had at least one read count in all the samples profiled. By this 
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Figure 3. Profiling of long a d small RNAs in exosome : read distribution (A) and length distribution
(B) of RNAs obtained from the total RNAseq protocol; read distribution of small RNAs (C) obtained
from the small RNAseq protocol; and percentage of reads mapping to different read lengths are
represented for microRNAs and piwi-interacting RNAs (D) and small nucleolar RNAs and transfer
RNAs (E).
Similarly, on average, about 3.1 million reads and 3.8 million reads were aligned to human
genome hg19 in control and cytokine-treated samples, respectively, from the small RNAseq protocol.
When annotated to different classes of small RNAs (Figure 3c), ~20% of the reads annotated to
miRNAs, followed by tRNAs (6.7%), piRNAs (0.8%), and snoRNAs (0.2%). The length distribution
of reads mapping to miRNAs ranged between 12 and 24 nt, with the highest peak observed at 22 nt,
indicating that the majority of reads mapped to mature miRNAs. However, reads mapping to piRNAs
were distributed between 12 and 31 nt, the highest percentage of reads were for 30 nt long transcripts,
conforming to the average read length of mature piRNAs (Figure 3d). Since snoRNAs and tRNAs are
generally longer than miRNAs and piRNAs, the length of reads mapping to snoRNAs and tRNAs
extended up to 90 nt and 77 nt, respectively (Figure 3e). The details of reads mapping to all samples
from total RNAseq and small RNAseq protocols are provided in Supplementary Tables S1a and
S1b, respectively.
2.3. Long and Small RNAs Are Differentially Expressed in Cytokine-Treated Islet-Derived Exosomes
Since the primary aim of our study was to identify potential circulating RNA biomarkers for T1D,
we applied a stringent criterion to filter the reads mapping to different classes of RNAs. We retained only
those RNAs that had at least one read count in all the samples profiled. By this criterion, we identified
17,013 mRNAs and 5711 lncRNAs from the total RNAseq protocol (Figure 4a), while 444 miRNAs, 175
piRNAs, 91 snoRNAs, and 167 tRNAs were identified from the small RNAseq protocol (Figure 4b).
A total of 133 mRNAs, 31 lncRNAs, 19 miRNAs, 25 piRNAs, 8 snoRNAs, and 20 tRNAs were found
to be differentially expressed with a fold change ≥1.3 (linear scale) and p < 0.05. The number of
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up- and down-regulated RNAs is reported in Figure 4c,d for long and small RNAs, respectively. In
general, the proportion of up- and down-regulated mRNAs and lncRNAs were distributed fairly evenly.
There were more upregulated miRNAs, while a higher proportion of piRNAs, snoRNAs, and tRNAs
were downregulated. The fold change values and p-values for differentially expressed RNAs identified
from the total RNAseq and small RNAseq protocols are provided in Supplementary Tables S2a and
S2b, respectively.
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2.4. Differentially Expressed RNAs Are Predicted to Play Key Functions Contributing to T1D Pathogenesis
2.4.1. mRNAs
Among the top ten upregulated mRNAs were ANG, CCDC107, USP39, and MAPK8IP1, and among
the top downregulated mRNAs were RBP4, BTAF1, CCNI, and TXK. Although not differentially
expressed, we found IAPP and Ins, in addition to other β cell identity markers, such as MAFA,
NEUROD1, NKX6.1, and FOXO1, and progenitor cell markers, such as NEUROG3, PAX4, and SOX9,
to be present in islet-derived exosomes. The functions of differentially expressed mRNAs were predicted
using Kyoto Encyclopedia of Genes and Genomes (KEGG) annotated pathways. We considered
all the pathways identified. The top enriched pathways were “signaling pathways regulating
pluripotency of stem cells”. This analysis also identified several critical pathways linked with diabetes
pathophysiology, including calcium signaling, insulin secretion, insulin signaling, and TGF-β signaling.
Representative pathways along with the genes involved in each pathway are shown in Table 1.
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Table 1. Pathways identified for differentially expressed mRNAs and lncRNAs.
Pathway Genes lncRNA
Pancreatic secretion, Insulin
secretion, Regulation of lipolysis
in adipocytes
ADCY8 AC034229.2,AP001372.2,ITGB2.AS1
cAMP signaling pathway ADCY8 AC034229.2,AP001372.2,ITGB2.AS1
DRD5
Chemokine signaling pathway ADCY8 AC034229.2,AP001372.2,ITGB2.AS1
GSK3A AC089998.1,AL031123.1,LINC01783
Calcium signaling pathway
ADCY8 AC034229.2,AP001372.2,ITGB2.AS1
PHKG2 AC239798.2,AL118505.1
DRD5
Lysosome AP3B1 AC110079.2,AL121603.2
Biosynthesis of amino acids CBS AC024614.4,AC239798.2,AL591623.1
Hippo signaling pathway
FRMD6 AC089998.1,AC105275.2,LINC01783
DLG3 AC010327.4,AL391987.3,CSNK1G2.AS1,LINC00967,LINC01258
BMP5 AC110079.2,AL121603.2
Glycine, serine, and threonine
metabolism
GRHPR AC092620.3,AL031123.1
CBS AC024614.4,AC239798.2,AL591623.1
Hematopoietic cell lineage,
Jak-STAT signaling pathway IL11 AC004949.1,AP001043.1
TGF-beta signaling pathway INHBE AC004949.1,AC034229.2,AC105275.2,AP001372.2
BMP5 AC110079.2,AL121603.2
Cytokine–cytokine receptor
interaction
INHBE AC004949.1,AC034229.2,AC105275.2,AP001372.2
TNFRSF13C AC110079.2,AL121603.2
IL11 AC004949.1,AP001043.1
Extracellular matrix-receptor
interaction LAMC1
Signaling pathways regulating
pluripotency of stem cells
PCGF5 AC239798.2,AL118505.1,MAP3K14.AS1,RP11.680G24.5
INHBE AC004949.1,AC034229.2,AC105275.2,AP001372.2
PCGF6 AC034229.3,RMRP
Insulin signaling pathway,
Glucagon signaling pathway PHKG2 AC239798.2,AL118505.1
B cell receptor signaling pathway PIK3AP1 AC004852.2,AC008669.1,AC110079.2,AL391987.3
PI3K-Akt signaling pathway PIK3AP1 AC004852.2,AC008669.1,AC110079.2,AL391987.3
LAMC1
Mitogen-Activated Protein Kinase
signaling pathway
PPP5D1 AC110079.2,AL121603.2,AL391261.2,AP001043.1
MAPK8IP1 AC089998.1,AC105275.2,LINC01783
Proteasome PSMD3 AC089998.1,AC105275.2,LINC01783
RNA transport RGPD1 CSNK1G2.AS1,ITGB2.AS1,LINC01258,RP11.475I24.8
RPP30 AC034229.3,AL391987.3,RMRP
Primary immunodeficiency,
NF-kappa B signaling pathway TNFRSF13C AC110079.2,AL121603.2
Spliceosome USP39 AC034229.3,AC092620.3,RMRP
Representative pathways identified from the KEGG database are indicated along with the differentially expressed
mRNAs involved in each pathway. The third column of the table lists the lncRNAs correlated with the mRNAs and
therefore potentially predicted to be involved in the corresponding pathways.
2.4.2. lncRNAs
lncRNAs are known to play a role in a diverse set of functions, including regulation of gene
expression and activation or inhibition of protein coding genes. Since there are no known predictive tools
for the functional enrichment analysis of lncRNAs, one way to understand the function of lncRNAs is to
identify the protein coding genes that correlate with the expression of lncRNAs. We used the variance
stabilized transformed counts of differentially expressed mRNAs and lncRNAs to run a Spearman’s
Int. J. Mol. Sci. 2019, 20, 5903 7 of 16
rank correlation and identified 362 pairs of lncRNA–mRNAs with r > 0.8 and p < 0.05 (Supplementary
Table S3). Of these, 173 pairs showed a positive correlation, suggesting that if the expression of a lncRNA
increases, the corresponding mRNA expression will also increase. However, 189 pairs were negatively
correlated, indicating that these pairs shared an inverse relationship. Since differentially expressed
mRNAs were used to predict the functions of lncRNAs, lncRNAs involved in the representative
pathway are indicated alongside mRNAs in Table 1.
2.4.3. miRNAs
Of the 444 miRNAs profiled in islet-derived exosomes, nineteen miRNAs were found to be
differentially expressed. hsa-miR-155-5p, a well-studied inflammatory miRNA, was found to
be the most upregulated miRNA, while hsa-miR-4485 was found to be the most downregulated
miRNA. To define potential mRNAs and pathways regulated by these miRNAs, target predictions for
differentially expressed miRNAs were performed using the miRNA target filter module in Ingenuity
Pathway Analysis tool (IPA). In silico predictions were overlapped with the differentially expressed
mRNAs to identify potential mRNA targets expressed within human islet-derived exosomes. A total
of 66 mRNAs were identified as potential targets for differentially expressed miRNAs (Supplementary
Table S4). Further, the core analysis module was used to predict the functions of miRNA–mRNA pairs.
We focused on “diseases and functions” results and excluded terms related to cancer (e.g., neoplasia,
cancer, neoplasm, and -oma). We found 19 functional terms with an activation z-score ≥0, and this
included terms such as “inflammation”, “synthesis of proteins”, “necrosis”, “synthesis of nitric oxide”,
“differentiation of stem cells” and “cytostasis”. The remaining predicted terms with no activation
score were not considered further. The list of functional terms with the genes and the corresponding
miRNAs are given in Supplementary Table S5a.
2.4.4. piRNAs
piRNAs are a class of small noncoding RNAs that associate with a class of Argonaute proteins
called P-element Induced WImpy testis (PIWI) proteins for their biogenesis and function. piRNAs have
predominantly been linked to germ cell/stem cell development and maintenance and transposon
regulation [12–15]. However, several studies have also demonstrated their gene regulatory potential
in somatic cells [16,17]. Furthermore, the stability of piRNAs in body fluids has also opened up the
possibility that piRNAs might serve as circulating biomarkers [18,19].
mRNA targets were predicted using the miRanda algorithm, with the focus on inverse relationship
targets, i.e., if a piRNA was upregulated, the corresponding mRNA targets were identified from the
group of downregulated genes and vice versa. Functions of the 25 differentially expressed piRNAs were
predicted using the same workflow used to predict miRNA targets. Similar to miRNAs, 16 functional
terms (exclusive of terms related to cancer) with an activation score≥0 were identified for piRNA targets
(Supplementary Table S5b). Since miRNAs and piRNAs share a similar gene regulatory mechanism by
binding to the 3′UTR of mRNAs, we aimed to identify the common functions that could potentially be
perturbed by both miRNAs and piRNAs. Eight functional terms were common between miRNA and
piRNA targets, suggesting a possible co-regulation of the pathways by two classes of small noncoding
RNAs. The common functional terms included “synthesis of proteins”, “quantity of mononuclear
leukocytes”, “quantity of lymphocytes”, “differentiation of adipocytes”, “necrosis”, “cell survival”,
“cell viability”, and “cellular homeostasis”. The representative common functions between miRNA
and piRNA targets are illustrated in Figure 5a. Additionally, 14 and 13 functional terms were unique to
miRNA and piRNA targets, respectively. The representative unique functions of miRNAs and piRNAs
are illustrated in Figure 5b,c, respectively.
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master regulators of gene expression. Since the post-transcriptional mechanisms are similar between
miRNAs and piRNAs, we identified the functions and target genes common to both classes of small
noncoding RNAs (A) as well as functions unique to miRNAs (B) and piRNAs (C).
2.4.5. snoRNAs and tRNAs
Since miRNAs and piR s have been demonstrated to be processed from larger RNAs such
as snoRNAs and tRNAs [20–23], it is hypothesized that snoRNAs and tRNAs may play an indirect
role in gene regulation. However, neither of these classes of small noncoding RNAs have been
well studied in the β cell or in T1D pathogenesis. In order to characterize these mechanisms in the
context of T1D, we overlapped the genomic boundaries of differentially expressed snoRNAs and
tRNAs with the genomic boundaries of miRNAs and piRNAs. One snoRNA (HBII-436: piR-36717
(DQ598651)) and three tRNAs (tRNA-Lys-TTT-2-1: piR-35463(DQ597397); tRNA-iMet-CAT-2-1:
piR-35176(DQ597110); and tRNA-Gly-GCC-2-4: piR-61648(DQ595536)) were identified to harbor
piRNAs. While HBII-436 and tRNA-Lys-TTT-2-1 were found to be downregulated along with the
embedded piRNAs, tRNA-iMet-CAT-2-1 and tRNA-Gly-GCC-2-4 were found to be upregulated along
with the embedded piRNAs. Interestingly, none of the differentially expressed miRNAs were predicted
to arise from within the genomic boundaries of snoRNAs or tRNAs.
3. Discussion
Reliable biomarkers capable of dissecting T1D-associated heterogeneity, guiding immunomodulatory
interventions, and identifying in ividuals at the highest risk of disease remains an unmet clinical need.
The ad ent f sequencing technologies has made it pos ible to obtain an ov rview of multiple classes
of RNAs with biological samples, spurring interest i the potential for protein coding and no coding
RNAs to serve as no invasive biomarkers of T1D (reviewed in [24] and [25]). C rcul ting RNAs,
such as miRNAs, faci itate cell-to-cell communication and exert important biological functions via
uptake of miRNAs by recipient cells, where they can act to modulat recipient cell gene regulatory
function. In addition, the presence of different RNA species in the blood has been proposed to indicate
cell lysis or turnover. Generally, RNAs are considered to be highly unstable as they are subjected to
degradation by RNases. However, the encapsulation of nucleic acids in membrane bound vesicles,
such as extracellular vesicles (EVs), limits the exposure of the encapsulated RNAs to degrading
enzymes, thus making them more stable in blood and other bodily fluids. Indeed, earlier studies
have demonstrated the release of EVs harboring nucleic acids from β cells undergoing stress [26].
In the case of T1D, specific nucleic acid signatures have been proposed to reflect processes such as β
cell death and stress and serve as a proxy of residual β cell mass and C-peptide production [27–30].
Thus, the possibility of combining cell- and disease-specific nucleic acid signatures with technology
that allows for the targeted identification of β cell-derived exosomes could have tremendous utility in
T1D biomarker strategies.
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Based on this premise, the goal of our study was to provide the first comprehensive map of
mRNAs and noncoding RNAs (long and small) from human islet-derived exosomes. The study of T1D
poses a unique challenge owing to the relative inaccessibility of the target organ for interrogation in
living individuals. However, during the development of T1D, the local pancreatic microenvironment
is enriched with invading immune cells, which are primed to release a number of proinflammatory
cytokines and chemokines [31–33]. Thus, we utilized a well-accepted ex vivo stress model to mimic
the proinflammatory milieu of T1D. This model involved treatment of human islets from nondiabetic
cadaveric donors with the cytokines IL-1β and IFN-γ, which was followed by RNA sequencing to
identify differentially expressed exosomal mRNAs, lncRNAs, miRNAs, piRNAs, snoRNAs, and tRNAs.
We identified this core set of RNAs by employing a stringent filtering cut-off of raw sequencing
reads, and our objective was to identify potential candidates with expression in all the samples used for
the study, increasing the likelihood of reproducibility. By this criterion, more than 50% of reads mapped
to protein coding mRNAs. In fact, mRNAs were identified as the most abundant class of RNAs in
islet-derived exosomes. However, our results showed that mRNAs are predominantly packaged as
fragments in EVs. Earlier studies have shown that these fragments may be functional byproducts of
full-length mRNAs, which upon entering the recipient cells may translate and become functional in
this new location [34]. Therefore, the identification of mRNA fragments may still suffice the need
to develop cell-specific signatures and to understand potential changes that cells undergo during
EV release.
Total RNA sequencing also revealed the presence of lncRNAs in islet-derived exosomes. lncRNAs
are an important class of noncoding RNAs, which play gene regulatory functions at the transcriptional,
epigenetic, and post-transcriptional levels. However, the roles of lncRNAs in the context of diabetes
remain less explored. Recently, Ruan et al. reported higher levels of lncRNA-p3134 in the blood of
individuals with type 2 diabetes, when compared to nondiabetic controls [35]. The higher expression of
lncRNA-p3134 also showed a positive correlation with fasting blood glucose, C-peptide, and HOMA-IR
levels, indicating a strong link between diabetes development and the levels of circulating lncRNAs.
Additionally, lncRNA-p3134 was also found to be associated with insulin secretion, β cell apoptosis,
and glucotoxicity. In the context of type 1 diabetes, this is the first study to report a comprehensive
list of lncRNAs in exosomes isolated from a model of T1D. Functional predictions of the differentially
expressed lncRNAs based on the correlated mRNAs suggest roles in insulin secretion and other
signaling pathways, such as the TGF-β signaling pathway.
In contrast to mRNAs and long noncoding RNAs, small noncoding RNAs, especially miRNAs
and piRNAs, are more stable in circulation, due to their small size and their encapsulation in
membrane bound vesicles [36,37]. In fact, several studies have reported the stability of miRNAs in
serum samples stored for up to 40 years [38]. Among the four classes of small noncoding RNAs,
~21% of reads mapped to miRNAs. Being a discovery study, we used a filter of ≥1.3 fold change
and p < 0.05 for identifying differentially expressed RNAs between untreated and cytokine-treated
islet-derived exosomes. Among the differentially expressed RNAs, approximately 50% of miRNAs
showed comparable results with those reported in literature. The top hit miRNA—miR-155-5p—has
been found to be upregulated in blood from children with T1D who were aged 6–11 years, with a disease
duration of 3.4 ± 1.9 years [39]. Similarly, miR-148a showed an elevated expression in serum and
plasma of children with recent onset T1D, adults with long-duration T1D and individuals with
latent autoimmune diabetes as well as those with pre- type 2 diabetes and type 2 diabetes (T2D).
Further, miR-146a-5p [40,41], miR-802 [42], and miR-17-5p [43] were found to be upregulated in adults
with T2D, similar to the expression pattern found in our analysis. Interestingly, some of the miRNAs
identified in this study, such as miR-130b [44] and miR-223-3p [45], have been reported to be associated
with diabetic complications, such as diabetic nephropathy or retinopathy.
Our data provide a comprehensive catalog of protein coding and noncoding RNAs in human
islet-derived exosomes from an ex vivo model of diabetes. Previous studies have shown that
the distribution of RNAs in exosomes is related to the parent cell type [46]. Since pancreatic
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islets are challenging to monitor for early disease development and progression, identification of
molecular markers released from the islets may serve as indicators of a change in the cellular status.
Circulating markers identified from patient-derived samples are often challenged with the question
of identifying the source of these markers, because serum and plasma host a milieu of molecules
from a variety of organs [47]. Studies such as ours may help narrow down the source of these
circulating biomarkers and provide information about the trajectory of disease progression along with
understanding the molecular functions of the identified biomarkers. However, the success of this
approach will likely be dependent on the parallel ability to identify EVs that are β-cell-derived based
on unique cell surface markers, as has been done in cancer [48]. Quite often, there has been some
controversy on the choice of endogenous reference controls for validation studies in human serum
or plasma samples [49]. Comprehensive profiling of RNAs from islet-derived exosomes may give us
an overview of the expression patterns of RNAs and provide a good base to search for endogenous
controls in biomarker studies related to T1D. While many studies have focused on miRNAs extensively,
our study includes the identification of newer classes of potential biomarkers for T1D as well, such as
piRNAs, snoRNAs, tRNAs, and lncRNAs, whose roles as biomarkers have been demonstrated in other
disease settings [16,22,50–54]. Validation of the study findings in clinical samples is warranted as it
may open up opportunities to explore beyond the well-studied classes of RNAs which can provide
a basis for building a comprehensive and intermolecular biomarker model for T1D.
4. Materials and Methods
4.1. Isolation of Exosomes from Human Islets
To profile protein coding and long noncoding RNAs, human islets from five cadaveric donors
were obtained from the Integrated Islet Distribution Program (IIDP), and their derived exosomes were
processed for total RNA sequencing. Human islets from ten donors were obtained for exosome-derived
small RNA sequencing; one islet donor was common between the two sequencing protocols. Islet donor
and isolation characteristics, including donor age, sex, Body Mass Index (BMI), cause of death,
measurements of islet purity and viability, ischemia duration, and culture time, are provided in
Supplementary Table S6, as per recent recommendations for the reporting of human islet characteristics
in research articles [55]. Human islets were provided from the IIDP in a de-identified manner. The study
was reviewed and approved as exempt by the Indiana University School of Medicine Institutional
Review Board. Upon receipt, cadaveric islets were cultured overnight in standard Prodo medium
(Prodo Labs, Aliso Viejo, CA, USA) that had been depleted for exosomes. In order to mimic the
proinflammatory conditions of T1D, islets were treated with or without 50 U/mL IL-1β and 1000 U/mL
IFN-γ for 24 h. After 24 h of cytokine treatment, the islet culture media was collected and centrifuged
for 30 min at 3000× g to remove cellular debris. The supernatant was recovered, and exosomes were
isolated using ExoQuick-TC (SBI Biosciences, Palo Alto, CA, USA), according to the manufacturer’s
protocol. The overall study workflow is illustrated in Figure 1.
4.2. Characterization of Exosomes
4.2.1. Nanoparticle Tracking Analysis (NTA)
The concentration and size distribution of the islet-derived exosomes were measured using
nanoparticle tracking analysis (ParticleMetrix, Inning am Ammersee, Germany) and analyzed using
Zetaview Analysis software. Briefly, human islet-derived exosomes were isolated using the methods
described above and maintained at −80 ◦C until batched analysis. On the day of analysis, samples were
thawed over ice and diluted in distilled water (1:3000). One milliliter of diluted sample was injected
for the measurement of exosome size and concentration using Zetaview software.
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4.2.2. Western Blot Analysis
Exosomes were isolated from human islet cell culture supernatant and lysed with protein lysis
buffer. The protein contents were measured using the Lowry method. A total of 10 µL of protein per
sample was electrophoresed on a 4–20% Bis-Tris gel (Bio-Rad, Hercules, CA, USA) under denaturing
conditions and blotted onto a PVDF membrane. The blots were blocked using LICOR blocking buffer
and probed for exosomal markers using the following primary antibodies: CD9 (SC5275, Santa Cruz,
CA, USA, mouse monoclonal) and CD63 (SC13118, Santa Cruz, CA, USA, mouse monoclonal).
LI-COR antimouse (1:10,000) secondary antibodies were used for the quantification of protein
expression. The data were quantified using ImageStudio (LI-COR, Lincoln, NE, USA).
4.2.3. Transmission Electron Microscopy (TEM) Analysis
Isolated exosomes were fixed with Karnovsky’s fixative (Electron Microscopy Sciences) and
processed with a series of ethanol washes. Washed samples were exchanged with fresh fixative,
microwaved, and then vacuum dried. Samples were washed again with cacodylate buffer and
processed with a solution containing 1% OsO4, 0.8% KFe(CN)6. Next, the samples were washed
twice with cacodylate buffer, followed by a wash with distilled water, then transferred into a solution
of 1% UA in distilled water, and dehydrated with a series of ethanol washes. Finally, the samples
were transferred into acetone, embedded in EMBed812 resin, and polymerized at 60 ◦C for 24 h.
Ultrathin sections (90 nm) were collected on copper grids and imaged in a JEOL 1230 TEM with 80 kV
accelerating voltage using a Gatan Orius camera.
4.3. RNA Isolation and Library Preparation
Total RNA was isolated using the SeraMir RNA isolation kit (SBI Biosciences, Palo Alto, CA, USA).
RNA quantification and quality were assessed by measuring the 260/280 ratio using a nanophotometer
(Implen, Munich, Germany). RNA integrity was evaluated using a Bioanalyzer 2100 (Agilent
Technologies, Santa Clara, CA, USA). Total RNA sequencing utilized 1–10 ng of RNA as the input.
Libraries for total RNA sequencing were prepared using Clontech SMARTer RNA Pico Kit v2, 96 rxns
(Takara, Kusatsu City, Japan). Sequencing was performed using Illumina HiSeq 4000 (75 bp paired-end
reads), generating 30 million reads per library.
For small RNA sequencing, 10–20 ng of RNA was used, and small RNA libraries were generated
using the Ion Total RNA-Seq Kit v2 User Guide, Pub. No. 4476286 Rev. E (Life Technologies,
Carlsbad, CA, USA). Each resulting barcoded library was quantified and then assessed for quality by
an Agilent Bioanalyzer. Multiple libraries were pooled in equal molarity and 8 µL of 100 pM pooled
libraries were applied to Ion Sphere Particles (ISPs) template preparation and amplification using Ion
OneTouch 2, followed by ISP loading onto a PI chip and sequencing on an Ion Proton semiconductor.
Sequence mapping was performed using Torrent Suite Software v4.6 (TSS 4.6).
4.4. Sequencing Data Analysis
Sequencing reads from both sequencing protocols were aligned to the human genome hg19
using STAR aligner v2.5.3a. Gencode v29 was used for annotating the total RNAseq reads to mRNAs
and long noncoding RNAs. The following databases were used for annotating the different classes
of small RNAs: mature miRNAs—miRBase v 20; piRNAs—National Center for Biotechnology
Information (NCBI); snoRNAs—The University of California Santa Cruz (UCSC) genome browser;
and tRNAs—tRNAdb. The annotation files for piRNAs, snoRNAs, and tRNAs were obtained from the
integrated database—Database of small human noncoding RNAs: DashR v2.0 [56]. For all the RNA
classes, only RNAs with a read count of at least one in all the samples were considered for downstream
analysis. Partek® Flow® software version 7.0.18.1030 (Copyright©; 2018 Partek Inc., St. Louis, MO,
USA) was used for aligning reads to the reference genome, annotating the reads to respective databases,
and for filtering reads for downstream analysis.
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Differential expression analysis between untreated and cytokine-treated exosomes was performed
for all RNAs using DESeq2 [57] paired sample analysis in the R statistical tool. Since this was a discovery
study with the objective of profiling different classes of RNAs, we considered RNAs exhibiting a fold
change of ≥1.3 (linear scale) and p < 0.05 as differentially expressed. The raw data files (fastq files),
raw counts, and variance stabilized normalized counts for total RNA sequencing were deposited in
the Gene Expression Omnibus (GEO accession ID: GSE139932). For small RNA sequencing, the raw
counts and variance stabilized normalized counts are provided in Supplementary Tables S7 and
S8, respectively.
4.5. Gene Enrichment Analysis
Pathways for differentially expressed mRNAs were identified using KEGG pathways built within
the Database for Annotation, Visualization, and Integrated Discovery (DAVID, http://david.abcc.
ncifcrf.gov/) [58,59]. Differentially expressed lncRNAs were correlated with differentially expressed
mRNAs. Spearman’s rank correlation was used for the analysis (“Hmisc” package in R statistical
program), and lncRNA–mRNA pairs showing correlation values >0.8 and p < 0.05 were considered as
significantly correlated pairs. mRNAs identified in the significant pairs were considered for pathway
analysis using DAVID to understand the functions of lncRNAs.
Targets for differentially expressed miRNAs were predicted using the Ingenuity Pathway
Analysis tool (QIAGEN Inc., Hilden, Germany, https://www.qiagenbioinformatics.com/products/
ingenuitypathway-analysis). The in silico predicted targets were further overlapped with the
differentially expressed mRNAs from the exosomes.
The targets of piRNAs were predicted using the miRanda algorithm. Complementary sequences
between differentially expressed piRNAs and the 3′UTR of differentially expressed mRNAs were
identified. piRNA–mRNA pairs with alignment scores ≥120 and energy scores ≤−15 kcal/mol (minus
15 kcal/mol) were considered for downstream analysis. The functions of miRNA–mRNA pairs and
piRNA–mRNA pairs were predicted using the “diseases and functions” option within the IPA core
analysis. For both miRNA and piRNAs, functional terms having any z-score were considered.
The function of snoRNAs and tRNAs were predicted based on the RNAs embedded within
snoRNAs and tRNAs. The genomic boundaries of differentially expressed snoRNAs and tRNAs (host
RNAs) were overlapped with the genomic boundaries of differentially expressed miRNAs and piRNAs
(embedded RNAs). Further, the direction of expression between the embedded RNAs and the host
RNAs were compared. RNA pairs showing the same direction of expression were considered for
further analysis. We followed the same method for the functional analysis of the embedded RNAs as
that of the previous functional analysis using miRNAs and piRNAs.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/23/
5903/s1. Supplementary Table S1: Mapping of reads; Supplementary Table S2: Differentially expressed RNAs;
Supplementary Table S3: mRNA-lncRNA correlated pairs; Supplementary Table S4: Targets of differentially
expressed miRNAs; Supplementary Table S5: Functional analysis of miRNAs and piRNAs; Supplementary Table
S6: Donor characteristics; Supplementary Table S7: Raw counts of small noncoding RNAs; Supplementary Table
S8: variance stabilized transformed counts of small noncoding RNAs.
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